Express Scripts' GenericsWork program
US pharmacy benefit manager Express Scripts has developed GenericsWork, a new program to help prescription benefit plan sponsors to save money through greater generic drug utilization without shifting costs to consumer members of their plans.
GenericsWork is built around Express Scripts' generics-based High Performance Formulary. It also includes educational tools on the clinical and economic value of generics.
Plan sponsors that implement GenericsWork will see their generic dispensing rate rise to some 70% of all drugs dispensed, says the PBM. Their annual drug cost trend (the increase in overall drug costs) will also be less than 5% for each of the next three years and they can elect to link their payments to Express Scripts to their annual trend under this program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze